Table I.
Clinical and molecular characteristics of patients (n = 181)
| Characteristics | All patients (n = 181) | Symptomatic brain metastasis (n = 49) | Asymptomatic brain metastasis (n = 132) |
|---|---|---|---|
| Gender: | |||
| Male | 82 (45.3%) | 22 (44.9%) | 60 (73.2%) |
| Female | 99 (54.7%) | 27 (55.1%) | 72 (54.5%) |
| Age [years]: | |||
| < 65 | 127 (70.2%) | 36 (73.5%) | 91 (70.2%) |
| ≥ 65 | 54 (29.8%) | 13 (26.5%) | 41 (29.8%) |
| ECOG PS: | |||
| 0–1 | 141 (77.9%) | 25 (51.0%) | 116 (87.9%) |
| 2 | 40 (22.1%) | 24 (49.0%) | 16 (12.1%) |
| Smoking status: | |||
| Yes | 60 (33.1%) | 19 (38.8%) | 41 (31.1%) |
| No | 121 (66.9%) | 30 (61.2%) | 91 (68.9%) |
| Pathological type: | |||
| Adenocarcinomas | 174 (96.1%) | 44 (89.8%) | 130 (98.5%) |
| Non-adenocarcinomas | 7 (3.9%) | 5 (10.2%) | 2 (1.5%) |
| Number of intracranial lesions: | |||
| 1–3 | 95 (52.5%) | 24 (49.0%) | 71 (53.8%) |
| ≥ 3 | 86 (47.5%) | 25 (51.0%) | 61 (46.2%) |
| RTOG GPA: | |||
| 0–1 | 50 (27.6%) | 15 (30.6%) | 35 (26.5%) |
| 1.5–2.5 | 104 (57.5%) | 27 (55.1%) | 77 (58.3%) |
| 3.0 | 17 (9.4%) | 4 (8.2%) | 13 (9.8%) |
| 3.5–4.0 | 10 (5.5%) | 3 (6.1%) | 7 (5.3%) |
| EGFR mutation: | |||
| Exon 19 | 99 (54.7%) | 29 (59.2%) | 70 (53.0%) |
| Exon 21L858R | 75 (41.4%) | 17 (34.7%) | 58 (43.9%) |
| Others | 7 (3.9%) | 3 (6.1%) | 4 (3.1%) |
| Type of EGFR-TKIs: | |||
| Icotinib | 153 (84.5%) | 37 (75.5%) | 116 (87.9%) |
| Gefitinib | 19 (10.5%) | 9 (18.4%) | 10 (7.6%) |
| Erlotinib | 9 (5.0%) | 3 (6.1%) | 6 (4.5%) |
| Line of treatment of EGFR-TKI: | |||
| First line | 96 (53.0%) | 25 (51.0%) | 71 (53.8%) |
| Second line or more | 85 (47.0%) | 24 (49.0%) | 61 (46.2%) |
| Brain treatment: | |||
| WBRT | 103 (56.9%) | 40 (81.6%) | 63 (47.7%) |
| SRS | 16 (8.8%) | 5 (10.2%) | 11 (8.3%) |
| No | 62 (34.3%) | 4 (8.2%) | 58 (44.0%) |
| Extracranial metastases: | |||
| Yes | 90 (49.7%) | 16 (32.7%) | 74 (56.1%) |
| No | 91 (50.3%) | 33 (67.3%) | 58 (43.9%) |